<DOC>
	<DOCNO>NCT02216656</DOCNO>
	<brief_summary>This randomize , placebo-controlled , double-blind ( included open arm KRN1493 ( cinacalcet ) ) , parallel-group , multi-center study design evaluate efficacy safety cohort comprise KHK7580 , placebo KRN1493 ( cinacalcet ) orally administer three week secondary hyperparathyroidism patient receive hemodialysis .</brief_summary>
	<brief_title>Phase 2 Study KHK7580</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Subjects voluntarily consent participate study Subjects stable chronic renal disease receive hemodialysis 3 time weekly least 12 week screen Subjects intact Parathyroid hormone &gt; = 240 pg/mL screen Subjects primary hyperparathyroidism Subjects receive cinacalcet hydrochloride within 2 week screen Subjects whose dose dose regimen active vitamin D drug derivative , phosphate binder , calcium preparation change start within 2 week screen . Subjects underwent parathyroidectomy and/or parathyroid intervention within 24 week screen . Subjects uncontrolled hypertension and/or diabetes Subjects severe heart disease . Subjects severe hepatic dysfunction . Subjects received investigational drug within 12 week screen Other subject unfit participation study judgment investigator sub investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>